250 related articles for article (PubMed ID: 21935950)
1. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity.
Lauer TM; Agrawal NJ; Chennamsetty N; Egodage K; Helk B; Trout BL
J Pharm Sci; 2012 Jan; 101(1):102-15. PubMed ID: 21935950
[TBL] [Abstract][Full Text] [Related]
2. Prediction of aggregation prone regions of therapeutic proteins.
Chennamsetty N; Voynov V; Kayser V; Helk B; Trout BL
J Phys Chem B; 2010 May; 114(19):6614-24. PubMed ID: 20411962
[TBL] [Abstract][Full Text] [Related]
3. Aggregation risk prediction for antibodies and its application to biotherapeutic development.
Obrezanova O; Arnell A; de la Cuesta RG; Berthelot ME; Gallagher TR; Zurdo J; Stallwood Y
MAbs; 2015; 7(2):352-63. PubMed ID: 25760769
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
[TBL] [Abstract][Full Text] [Related]
5. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
6. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations.
Wang X; Kumar S; Buck PM; Singh SK
Proteins; 2013 Mar; 81(3):443-60. PubMed ID: 23065923
[TBL] [Abstract][Full Text] [Related]
7. Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs.
Clark RH; Latypov RF; De Imus C; Carter J; Wilson Z; Manchulenko K; Brown ME; Ketchem RR
MAbs; 2014; 6(6):1540-50. PubMed ID: 25484048
[TBL] [Abstract][Full Text] [Related]
8. A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers.
Heads JT; Kelm S; Tyson K; Lawson ADG
MAbs; 2022; 14(1):2138092. PubMed ID: 36418193
[TBL] [Abstract][Full Text] [Related]
9. Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies.
Jetha A; Thorsteinson N; Jmeian Y; Jeganathan A; Giblin P; Fransson J
MAbs; 2018; 10(6):890-900. PubMed ID: 30110240
[TBL] [Abstract][Full Text] [Related]
10. Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold.
Perchiacca JM; Lee CC; Tessier PM
Protein Eng Des Sel; 2014 Feb; 27(2):29-39. PubMed ID: 24398633
[TBL] [Abstract][Full Text] [Related]
11. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
[TBL] [Abstract][Full Text] [Related]
12. AggScore: Prediction of aggregation-prone regions in proteins based on the distribution of surface patches.
Sankar K; Krystek SR; Carl SM; Day T; Maier JKX
Proteins; 2018 Nov; 86(11):1147-1156. PubMed ID: 30168197
[TBL] [Abstract][Full Text] [Related]
13. Predicting the Agitation-Induced Aggregation of Monoclonal Antibodies Using Surface Tensiometry.
Shieh IC; Patel AR
Mol Pharm; 2015 Sep; 12(9):3184-93. PubMed ID: 26198590
[TBL] [Abstract][Full Text] [Related]
14. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
15. Impact of short range hydrophobic interactions and long range electrostatic forces on the aggregation kinetics of a monoclonal antibody and a dual-variable domain immunoglobulin at low and high concentrations.
Kumar V; Dixit N; Zhou LL; Fraunhofer W
Int J Pharm; 2011 Dec; 421(1):82-93. PubMed ID: 21959107
[TBL] [Abstract][Full Text] [Related]
16. Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity.
Yamniuk AP; Ditto N; Patel M; Dai J; Sejwal P; Stetsko P; Doyle ML
J Pharm Sci; 2013 Aug; 102(8):2424-39. PubMed ID: 23712759
[TBL] [Abstract][Full Text] [Related]
17. Electrostatic interactions modulate the differential aggregation propensities of IgG1 and IgG4P antibodies and inform charged residue substitutions for improved developability.
Heads JT; Lamb R; Kelm S; Adams R; Elliott P; Tyson K; Topia S; West S; Nan R; Turner A; Lawson ADG
Protein Eng Des Sel; 2019 Dec; 32(6):277-288. PubMed ID: 31868219
[TBL] [Abstract][Full Text] [Related]
18. Insights into the potential aggregation liabilities of the b12 Fab fragment via elevated temperature molecular dynamics.
Buck PM; Kumar S; Singh SK
Protein Eng Des Sel; 2013 Mar; 26(3):195-205. PubMed ID: 23188804
[TBL] [Abstract][Full Text] [Related]
19. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions.
Agrawal NJ; Kumar S; Wang X; Helk B; Singh SK; Trout BL
J Pharm Sci; 2011 Dec; 100(12):5081-95. PubMed ID: 21789769
[TBL] [Abstract][Full Text] [Related]
20. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.
Perchiacca JM; Ladiwala AR; Bhattacharya M; Tessier PM
Protein Eng Des Sel; 2012 Oct; 25(10):591-601. PubMed ID: 22843678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
